Jan 22, 2014 by Dave WilliamsonAre Insurers Preparing to Quit Obamacare? Plus, 4 Must-Watch Dates for InvestorsAre some big insurers planning to walk away from Obamacare?
Jan 22, 2014 by Dave WilliamsonBehind the Headline: Johnson & Johnson's Fourth-Quarter Earnings DecodedSeveral headlines emerged today praising Johnson & Johnson's soaring earnings after it announced Q4 numbers today. But just beneath the surface, things may not be quite so rosy.
Jan 22, 2014 by Dave WilliamsonWhy Amarin Corporation PLC Lost Big, and What's Next for Its Fish Oil DrugHere's why Amarin fell off a cliff today, and where the company goes from here.
Jan 19, 2014 by Dave WilliamsonGoogle Glass to Google Contacts: The Game-Changing Diabetes Device You Need to WatchFrom Google Glass to Google contacts?
Jan 18, 2014 by Dave WilliamsonFriday's Biggest Health-Care Loser: Nu Skin Enterprises, Inc.Shares of Nu Skin continue their freefall, after reports from China indicate that its government will be investigating the company on suspicion of a pyramid scheme.
Jan 18, 2014 by Dave Williamson2014 Trend Alert: Health-Care M&AAre Bristol-Myers Squibb and Teva on the hunt for some M&A opportunities?
Jan 18, 2014 by Dave WilliamsonFriday's Biggest Health-Care Winner: Illumina, Inc.Illumina's new machine could be enormous for genome processing, and for investors.
Jan 18, 2014 by Dave WilliamsonMyth Busting: Insurers Hate ObamacareIs Obamacare as bad for insurers as some would believe?
Jan 15, 2014 by Dave WilliamsonChelsea Therapeutics International Ltd Wins Huge Vote of Confidence. Can It Stop Another FDA Rejection?Chelsea wins another advisory committee, but will Northera's fate be any different?
Jan 15, 2014 by Dave WilliamsonVIVUS, Inc. and Aetna Inc's New Weight Loss PlanCould Vivus' new weight loss partnership with Aetna be a big boost to this year's sales?
Jan 15, 2014 by Dave Williamson and Max MacalusoWill the Shorts Keep Hating Dendreon Corporation in 2014?Dendreon was a favorite of short-sellers in 2013. Could 2014 be the year Dendreon gets some market love?
Jan 14, 2014 by Dave WilliamsonAsk a Fool: Gilead Sciences on a Downward Trend -- Should I Hold Firm?Is Gilead Sciences still a stock to hold for the long term?
Jan 13, 2014 by Dave WilliamsonAlnylam Pharmaceuticals, Inc.: Big Pharma Loves This StockSanofi takes a 12% position in Alnylam.
Jan 13, 2014 by Dave WilliamsonIntercept Pharmaceuticals Inc: What Goes Up Must Come DownIntercept has its first pullback since its amazing two-day six-bagger run.
Jan 13, 2014 by Dave WilliamsonObamacare More Adverse Than AnticipatedThe enrollment data is out, and Humana's concerns may be justified.
Jan 12, 2014 by Dave WilliamsonBig Changes and Small Moves for Teva Pharmaceutical Industries Ltd.Teva finds a a new CE and ignites a bidding war for a potential acquisition.
Jan 11, 2014 by Dave WilliamsonAsk a Fool: Is Gilead Sciences, Inc. a Sell?Can Gilead's big run in 2013 be replicated in 2014?
Jan 9, 2014 by Dave WilliamsonIntercept Pharmaceuticals Inc: A Whole New Class of Blockbuster Drug Is BornWhy Intercept Pharmaceuticals just quadrupled and Conatus Pharmaceuticals saw a 70% gain.
Jan 7, 2014 by Dave WilliamsonPharmacyclics Inc. Crushes Critical TrialPharmacyclics shot up nearly 20% today, after phenomenal results in this critical trial. But what about competition from Roche and AbbVie?
Jan 6, 2014 by Dave WilliamsonCell Therapeutics Inc. Soars AgainAnother explosive day on the market for biotech company Cell Therapeutics, but is there trouble brewing beneath the surface of this alluring market performer that should scare investors off?
